PR-104 in Treating Patients With Advanced Solid Tumors

DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed solid tumor, meeting 1 of the following criteria:

  * Not amenable to standard therapy
  * Refractory to conventional therapy
* Measurable or evaluable disease

PATIENT CHARACTERISTICS:

* Karnofsky performance status 70-100%
* Life expectancy \> 3 months
* Absolute neutrophil count ≥ 1,500/mm³
* Platelet count ≥ 100,000/mm³
* Hemoglobin \> 9 g/L (transfusion independent)
* Bilirubin ≤ 1.5 times upper limit of normal (ULN)
* ALT and AST ≤ 2.5 times ULN
* Creatinine clearance ≥ 60 mL/min
* PT/INR or aPTT ≤ 1.1 times ULN
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 30 days after completion of study treatment
* No significant cardiac comorbidity including any of the following:

  * New York Heart Association class III-IV congenital heart failure
  * LVEF \< 40%
  * Unstable angina
  * Myocardial infarction within the past 6 months
  * Ventricular arrhythmias requiring drug therapy
  * Pacemaker or implanted defibrillator
* No ongoing coagulopathy
* No uncontrolled infection or infection requiring parenteral antibiotics
* No other significant clinical disorder or laboratory finding that would preclude study treatment
* No known HIV positivity
* No known positivity for hepatitis B surface antigen or hepatitis C with abnormal liver tests
* No known allergy to nonplatinum-containing alkylating agents

PRIOR CONCURRENT THERAPY:

* Recovered from prior therapy
* More than 2 weeks since prior hormonal therapy (except for androgen-deprivation therapy)
* More than 4 weeks since prior major surgery
* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
* More than 4 weeks since prior radiotherapy
* More than 1 month since prior investigational drugs, therapies, or devices
* No prior radiotherapy to \> 25% of bone marrow
* No prior high-dose chemotherapy, either myeloablative or nonmyeloablative (mini-allogeneic transplant)
* No more than 3 prior myelosuppressive chemotherapy regimens
* Concurrent steroids allowed provided dose is stable for ≥ 2 weeks and clinical condition is stable for 1 month

  * Nasal, opthalmologic, and topical glucocorticoid preparations allowed
  * Physiologic hormone replacement therapies allowed (i.e., oral replacement glucocorticoid therapy for adrenal insufficiency)
* No concurrent prophylactic hematopoietic growth factors
* No concurrent radiotherapy, including local palliative radiotherapy or systemic radioisotopes

  * Radioisotopes for protocol specified positron emission tomography allowed
* No other concurrent investigational agents
* No other concurrent chemotherapy, radiotherapy (including palliative local radiotherapy), hormonal therapy (except for androgen-deprivation therapy), and/or biological therapy (including immunotherapy)